Please login to the form below

Not currently logged in
Email:
Password:

Phytopharm

This page shows the latest Phytopharm news and features for those working in and with pharma, biotech and healthcare.

Phytopharm shares dive as Parkinson's drug fails

Phytopharm shares dive as Parkinson's drug fails

Phytopharm shares dive as Parkinson's drug fails. Stock falls 80 per cent after Cogane failure in phase II. ... The latest disappointment comes after Phytopharm switched its initial focus on complex plant extract-derived pharmaceuticals.

Latest news

  • Still afloat

    Some cash-strapped but entrepreneurial examples include Cambridgeshire-based Phytopharm, whose novel molecule for Parkinson's and Alzheimer's has reversed the loss of dopaminergic neurones (restoring learning and memory ability)

  • Pharma news in brief

    Cash blow for Phytopharm. Phytopharm, which specialises in developing medicines from plants, reassured investors that finances were still strong, following the abrupt end to a £24m fund raising deal. ... However, Richard Dixey, Phytopharm's chief

  • Pharma news in brief

    Plant product firm reaches milestone. Biotech company Phytopharm, which specialises in generating medical products from plant extracts, has achieved its first interim profit as milestone payments from licensing partners rolled in. ... Phytopharm was also

  • R&D news in brief

    Phytopharm plans fundraising. Biopharmaceutical company Phytopharm, is planning to raise £23.9m through a UK placing, US private placing and open offer of 13.3m new shares. ... Phytopharm secured a licensing deal with Unilever in December 2004 for the

  • Pharma news in brief

    Phytopharm seeks bargaining funds. Phytopharm, a pharmaceutical plant-product research company, is seeking to raise £23.9m to strengthen its negotiating position with licensing partners.

More from news
Approximately 1 fully matching, plus 24 partially matching documents found.

Latest Intelligence

  • Pharma deals during February 2013 Pharma deals during February 2013

    Another failure this month has been Phytopharm's phase II compound, Cogane, in early stage Parkinson's disease. ... As Phytopharm does not have a portfolio of other late stage projects to develop in place of Cogane, the company is looking at “ other

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics